USFDA okays Zydus Cadila Ursodiol Capsules, while tentative nod to Linagliptin, Metformin Hydrochloride Tablets
Ahmedabad: Drugmaker, Zydus Cadila, has recently announced that the company has received final approval from the US Food & Drug Administration (USFDA) to market Ursodiol Capsules USP, 300 mg (US RLD: Actigall Capsules).
Ursodiol is in a class of medications called gallstone dissolution agents. It is used to treat people with primary biliary cirrhosis (PBC; an autoimmune liver disease).
The company also received tentative approval from the USFDA to market Linagliptin and Metformin Hydrochloride Tabs (US RLD: Jentadueto Tablets) in the strengths of 2.5 mg/500 mg, 2.5 mg/850 mg, and 2.5 mg/1,000 mg.
It is used along with diet and exercise to improve control of blood sugar levels in adults with type 2 diabetes mellitus.
Both drugs will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.
The group now has 307 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.
Read also: Zydus Cadila gets USFDA okay for Fingolimod Capsules, Verapamil Hydrochloride Injection
Zydus Cadila is a global pharmaceutical company headquartered in Ahmedabad, India.
The company discovers, develops, manufactures, and markets a broad range of healthcare therapies.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd